Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen
Abstract Background It remains controversial whether palliative primary tumor resection (PPTR) can provide survival benefits to the patients with metastatic colorectal cancer (mCRC) who have unresectable metastases. The aim of this study was to evaluate whether PPTR could improve the survival of pat...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2016-06-01
|
Series: | Chinese Journal of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40880-016-0120-4 |
id |
doaj-16a89ab28a3043139e48f38352ff38f3 |
---|---|
record_format |
Article |
spelling |
doaj-16a89ab28a3043139e48f38352ff38f32020-11-24T22:21:04ZengBMCChinese Journal of Cancer1944-446X2016-06-013511810.1186/s40880-016-0120-4Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigenWen-Zhuo He0Yu-Ming Rong1Chang Jiang2Fang-Xin Liao3Chen-Xi Yin4Gui-Fang Guo5Hui-Juan Qiu6Bei Zhang7Liang-Ping Xia8State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterAbstract Background It remains controversial whether palliative primary tumor resection (PPTR) can provide survival benefits to the patients with metastatic colorectal cancer (mCRC) who have unresectable metastases. The aim of this study was to evaluate whether PPTR could improve the survival of patients with mCRC. Methods We conducted a retrospective study on consecutive mCRC patients with unresectable metastases who were diagnosed at Sun Yat-sen University Cancer Center in Guangzhou, Guangdong, China, between January 2005 and December 2012. Overall survival (OS) and progression-free survival (PFS) after first-line chemotherapy failure were compared between the PPTR and non-PPTR patient groups. Results A total of 387 patients were identified, including 254 who underwent PPTR and 133 who did not. The median OS of the PPTR and non-PPTR groups was 20.8 and 14.8 months (P < 0.001), respectively. The median PFS after first-line chemotherapy was 7.3 and 4.8 months (P < 0.001) in the PPTR and non-PPTR groups, respectively. A larger proportion of patients in the PPTR group (219 of 254, 86.2%) showed local progression compared with that of patients in the non-PPTR group (95 of 133, 71.4%; P < 0.001). Only patients with normal lactate dehydrogenase (LDH) levels and with carcinoembryonic antigen (CEA) levels <70 ng/mL benefited from PPTR (median OS, 22.2 months for the PPTR group and 16.2 months for the non-PPTR group; P < 0.001). Conclusions For mCRC patients with unresectable metastases, PPTR can improve OS and PFS after first-line chemotherapy and decrease the incidence of new organ involvement. However, PPTR should be recommended only for patients with normal LDH levels and with CEA levels <70 ng/mL.http://link.springer.com/article/10.1186/s40880-016-0120-4Metastatic colorectal cancerPalliative primary tumor resectionOverall survivalLactate dehydrogenaseCarcinoembryonic antigen |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wen-Zhuo He Yu-Ming Rong Chang Jiang Fang-Xin Liao Chen-Xi Yin Gui-Fang Guo Hui-Juan Qiu Bei Zhang Liang-Ping Xia |
spellingShingle |
Wen-Zhuo He Yu-Ming Rong Chang Jiang Fang-Xin Liao Chen-Xi Yin Gui-Fang Guo Hui-Juan Qiu Bei Zhang Liang-Ping Xia Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen Chinese Journal of Cancer Metastatic colorectal cancer Palliative primary tumor resection Overall survival Lactate dehydrogenase Carcinoembryonic antigen |
author_facet |
Wen-Zhuo He Yu-Ming Rong Chang Jiang Fang-Xin Liao Chen-Xi Yin Gui-Fang Guo Hui-Juan Qiu Bei Zhang Liang-Ping Xia |
author_sort |
Wen-Zhuo He |
title |
Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen |
title_short |
Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen |
title_full |
Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen |
title_fullStr |
Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen |
title_full_unstemmed |
Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen |
title_sort |
palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen |
publisher |
BMC |
series |
Chinese Journal of Cancer |
issn |
1944-446X |
publishDate |
2016-06-01 |
description |
Abstract Background It remains controversial whether palliative primary tumor resection (PPTR) can provide survival benefits to the patients with metastatic colorectal cancer (mCRC) who have unresectable metastases. The aim of this study was to evaluate whether PPTR could improve the survival of patients with mCRC. Methods We conducted a retrospective study on consecutive mCRC patients with unresectable metastases who were diagnosed at Sun Yat-sen University Cancer Center in Guangzhou, Guangdong, China, between January 2005 and December 2012. Overall survival (OS) and progression-free survival (PFS) after first-line chemotherapy failure were compared between the PPTR and non-PPTR patient groups. Results A total of 387 patients were identified, including 254 who underwent PPTR and 133 who did not. The median OS of the PPTR and non-PPTR groups was 20.8 and 14.8 months (P < 0.001), respectively. The median PFS after first-line chemotherapy was 7.3 and 4.8 months (P < 0.001) in the PPTR and non-PPTR groups, respectively. A larger proportion of patients in the PPTR group (219 of 254, 86.2%) showed local progression compared with that of patients in the non-PPTR group (95 of 133, 71.4%; P < 0.001). Only patients with normal lactate dehydrogenase (LDH) levels and with carcinoembryonic antigen (CEA) levels <70 ng/mL benefited from PPTR (median OS, 22.2 months for the PPTR group and 16.2 months for the non-PPTR group; P < 0.001). Conclusions For mCRC patients with unresectable metastases, PPTR can improve OS and PFS after first-line chemotherapy and decrease the incidence of new organ involvement. However, PPTR should be recommended only for patients with normal LDH levels and with CEA levels <70 ng/mL. |
topic |
Metastatic colorectal cancer Palliative primary tumor resection Overall survival Lactate dehydrogenase Carcinoembryonic antigen |
url |
http://link.springer.com/article/10.1186/s40880-016-0120-4 |
work_keys_str_mv |
AT wenzhuohe palliativeprimarytumorresectionprovidessurvivalbenefitsforthepatientswithmetastaticcolorectalcancerandlowcirculatinglevelsofdehydrogenaseandcarcinoembryonicantigen AT yumingrong palliativeprimarytumorresectionprovidessurvivalbenefitsforthepatientswithmetastaticcolorectalcancerandlowcirculatinglevelsofdehydrogenaseandcarcinoembryonicantigen AT changjiang palliativeprimarytumorresectionprovidessurvivalbenefitsforthepatientswithmetastaticcolorectalcancerandlowcirculatinglevelsofdehydrogenaseandcarcinoembryonicantigen AT fangxinliao palliativeprimarytumorresectionprovidessurvivalbenefitsforthepatientswithmetastaticcolorectalcancerandlowcirculatinglevelsofdehydrogenaseandcarcinoembryonicantigen AT chenxiyin palliativeprimarytumorresectionprovidessurvivalbenefitsforthepatientswithmetastaticcolorectalcancerandlowcirculatinglevelsofdehydrogenaseandcarcinoembryonicantigen AT guifangguo palliativeprimarytumorresectionprovidessurvivalbenefitsforthepatientswithmetastaticcolorectalcancerandlowcirculatinglevelsofdehydrogenaseandcarcinoembryonicantigen AT huijuanqiu palliativeprimarytumorresectionprovidessurvivalbenefitsforthepatientswithmetastaticcolorectalcancerandlowcirculatinglevelsofdehydrogenaseandcarcinoembryonicantigen AT beizhang palliativeprimarytumorresectionprovidessurvivalbenefitsforthepatientswithmetastaticcolorectalcancerandlowcirculatinglevelsofdehydrogenaseandcarcinoembryonicantigen AT liangpingxia palliativeprimarytumorresectionprovidessurvivalbenefitsforthepatientswithmetastaticcolorectalcancerandlowcirculatinglevelsofdehydrogenaseandcarcinoembryonicantigen |
_version_ |
1725772453808963584 |